Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
ErCb demonstrated favorable efficacy and tolerability in patients with heavily pre-treated mBC, especially TNBC. The findings of the current study warrant further investigation of the application of this combination in earlier lines of mBC treatment.
Authors
- Zhongyu Yuan (ORCID: https://orcid.org/0000-0002-2920-9671)
- Xiuyue Li
- Anli Yang (ORCID: https://orcid.org/0000-0003-0966-7285)
- Lidong Zhang (ORCID: https://orcid.org/0009-0006-1013-918X)
- Xin An (ORCID: https://orcid.org/0000-0003-0683-5511)
- Mengqian Ni
- Meiting Chen (ORCID: https://orcid.org/0000-0002-7195-1300)
- Lijia Zhou
- Yanxia Shi
- Lixia Li (ORCID: https://orcid.org/0000-0002-7382-2190)
- Shusen Wang (ORCID: https://orcid.org/0000-0003-0139-5780)
- Fei Xu (ORCID: https://orcid.org/0009-0000-2452-937X)
- Yongkui Lu
- Lulu Zhang (ORCID: https://orcid.org/0000-0001-6754-9127)
- Dachuan Guo
Institutions
- Sun Yat-sen University (CN)
- Guangxi Medical University (CN)
- Guangdong Medical College (CN)
- Wenzhou Medical University (CN)
- Panyu District Central Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Tumor Hospital of Guangxi Medical University (CN)
- Dongyang People's Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1186/s12885-024-12953-9
- Citations
- 3
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China